Skip to content

Home - Research - Our pipeline summary    
AstraZeneca pipeline summary

New chemical entities and line extensions

AstraZeneca's line extensions (LE) and new chemical entities (NCEs) are listed in the tables below, sorted by therapy area (TA). Please use the links opposite to navigate this page.

Our pipeline summary is available to download (PDF 89 kb). This information was updated after our Fourth quarter and full year results announced Thursday, 31 Janaury 2008.

Line extensions

Compound
Mechanism
Area under
investigation
Phase
Estimated Filing
MAANDA
Cardiovascular
Atacandangiotensin II antagonistdiabetic retinopathyIII1H 20091H 2009
Atacand Plusangiotensin II antagonist
/ thiazide diuretic		32/12.5 mg, 32/25 mg for hypertensionIII2Q 2008
CrestorstatinatherosclerosisIIILaunchedLaunched
Crestorstatinoutcomes End Stage
Renal Disease		III1H 20091H 2009
Crestorstatin outcomes in subjects with elevated CRP III 2010 2010
Saxagliptin/
Metformin FDC		DPP-4 + biguanide FDCdiabetesIII
Dapagliflozin/
Metformin FDC		SGLT2 + biguanide FDC diabetesIII  
Gastrointestinal
Nexiumproton pump inhibitorpeptic ulcer bleedingIII2Q 20082Q 2008
Nexium Sachet
formulation		proton pump inhibitorGERDIIIApproved **Launched
Nexiumproton pump inhibitorextra-oesophageal
reflux disease		II2H 2009*2H 2009*
Nexium low dose
aspirin
combination		proton pump inhibitorlow dose aspirin
associated peptic ulcer		III1H 2009
Neuroscience
Seroquel XRD2/5HT2 antagonistschizophreniaIIIApprovedLaunched
SeroquelD2/5HT2 antagonistbipolar maintenanceIII2Q 2008Filed
SeroquelD2/5HT2 antagonistbipolar depressionIII1Q 2008Launched
Seroquel XRD2/5HT2 antagonistgeneralised anxiety
disorder		III4Q 20082Q 2008
Seroquel XRD2/5HT2 antagonistmajor depressive
disorder		III3Q 20081Q 2008
Seroquel XRD2/5HT2 antagonistbipolar maniaIII1Q 2008Filed
Seroquel XRD2/5HT2 antagonistbipolar depressionIII1Q 2008Filed
Oncology & Infection
Faslodexoestrogen receptor
antagonist		1st line advanced
breast cancer		III
Faslodexoestrogen receptor
antagonist		adjuvantIII
IressaEGFR-TK inhibitorNSCLCIII2Q 2008 
FluMist
(MedImmune)		live, attenuated,
intranasal influenza virus vaccine		 influenza III 2Q 2008 Launched
*Project Extraesophageal reflux disease (reflux asthma) will be completed but will not result in a regulatory filing.
** Approved by EU RMS, Mutual Recognition Procedure ongoing.
Respiratory & Inflammation
Symbicort pMDIinhaled steroid/fast
onset, long-acting ß2
agonist		asthmaIIIFiled*Launched
**
Symbicort pMDIinhaled steroid/fast
onset, long-acting ß2
agonist		COPDIIIFiled*2Q 2008

* To be supplemented in 2008 with data supporting two additional strengths
** US approval based on 12 years and above

Back to top

New chemical entities (NCEs) - Phase III

Compound
Mechanism
Area under
investigation
Phase
Estimated Filing
MAANDA
Cardiovascular
AZD6140ADP receptor antagonistarterial thrombosisIII2H 20092H 2009
Saxagliptindipeptidyl peptidase-4
(DPP-4) inhibitor		diabetesIII2H 20092Q 2008
Dapagliflozinsodium-glucose cotransporter-2 (SGLT2) inhibitordiabetes III20102010
Crestor/
ABT-335
statin + fibrate fixed combination dyslipidaemiaIII 2H 2009
Neuroscience
PN400naproxen
+esomeprazole		signs and symptoms
of OA , RA, and AS		III1H 20091H 2009
Oncology & Infection
ZactimaVEGF/EGF TK inhibitor
with RET kinase activity		NSCLCIII4Q 20084Q 2008
Recentin
VEGF signalling inhibitor
(VEGFR-TKI)		NSCLC and CRCII/III20102010
RecentinVEGF signalling inhibitor
(VEGFR-TKI)		recurrent
glioblastoma		 III 2010 2010
ZD4054endothelin A receptor
antagonist		hormone resistant
prostate cancer		 III20112011
Motavizumab
(MedImmune)		humanized monoclonal
antibody		RSV prevention III1H 20091Q 2008

 

Back to top

New chemical entities (NCEs) - Phases I and II

Compound
Mechanism
Area under
investigation
Phase
Estimated Filing
MAANDA
Cardiovascular
AZD0837thrombin inhibitorthrombosisII20122012
AZD4121cholesterol absorption
inhibitor		dyslipidaemiaII 
AZD2207CB1 antagonist diabetes/obesity II  
AZD1175CB1 antagonistdiabetes/obesityI
AZD1305antiarrhythmicarrhythmiasI
AZD6370GLK activatordiabetesI
Gastrointestinal
AZD3355inhibitor of transient lower oesophageal
sphincter relaxations
(TLESR)		GERDII20112011
AZD2066metabotropic Glutamate receptors subtype 5GERDI
AZD1386Vanilloid receptor 1 antagonistGERDI
Neuroscience
AZD3480neuronal nicotinic receptor agonistcognitive disorders in schizophreniaII20112011
AZD3480neuronal nicotinic receptor agonistAlzheimersII20112011
AZD6765NMDA receptor antagonistdepressionII
AZD2327enkephalinergic receptor
modulator		anxiety and
depression		I
AZD5904inhibitor of myeloperoxidase (MPO)multiple sclerosisI
AZD3241inhibitor of myeloperoxidase (MPO)Parkinson's diseaseI
AZD0328selective neuronal nicotinic receptor agonistAlzheimersI
AZD1940CB receptor agonistnociceptive and neuropathic painI
AZD2624NK receptor agonistschizophreniaI
AZD1386Vanilloid receptor antagonistchronic nociceptive painI
AZD2066metabotropic Glutamate receptorschronic nociceptive painI
AZD7325GABA receptor subtype partial agonistanxietyI
AZD6280GABA receptor subtype partial agonistanxietyI
TC-5619
(Targacept)		neuronal nicotinic receptor agonistcognitive disorders in schizophreniaI
Oncology & Infection
ZactimaVEGF/EGF TK inhibitor with RET kinase activitymedullary thyroid cancerII4Q
2008		4Q
2008
CytoFabanti-TNF-alpha
polyclonal antibody		severe sepsisII
AZD6244
(ARRY-142886)		MEK inhibitorsolid tumoursII
AZD2281PARP inhibitorbreast cancerII
EBV vaccine*
Epstein-Barr Virus Vaccinepost-transplant proliferative diseaseII
AZD28365a repliconhepatitis CII
AZD0530SRC kinase inhibitorsolid tumours and
haematological
malignancies		II
MEDI-524
(Motavizumab)
MAb targets F-Proteinearly & late
treatment of disease
in paeds > 1 yr		II
MEDI-561
HSP 90 inhibitorsolid tumoursII2010
AZD1152aurora kinase inhibitorsolid tumours and
haematological
malignancies		I
AZD4769EGFR tyrosine kinase inhibitorsolid tumoursI
AZD4877Cell Cycle Agentsolid tumours and
haematological
malignancies		I
AZD8931erbB kinase inhibitorsolid tumoursI
AZD7762CHK1 kinase inhibitorsolid tumoursI
AZD8330
(ARRY-424704)		MEK inhibitorsolid tumoursI
CAT-8015recombinant
immunotoxin		haematological
malignancies		I
MEDI-534
RSV/PIV-3 vaccineintranasal
immunisation		I
MEDI-560
PIV-3 vaccineintranasal
immunisation		I
H5N1
H5N1 influenza virus vaccinepandemic influenza
vaccine		I
MEDI-538CD19 B cellsleukemia/lymphomaI
MEDI-564
F protein inhibitorRSV treatmentI
CMV vaccineCMV vaccine cytomegalovirus I   
MEDI-557YTE - extended half-life RSV Mab RSV Prophylaxis I  
Respiratory & Inflammation
AZD9056ion channel blocker (P2X7)rheumatoid arthritisII20122012
AZD1981Prostaglandin receptor antagonistasthmaII
AZD5672Chemokine antagonist (CCR5)rheumatoid arthritisII20122012
MEDI-528
anti-IL-9 antibodyasthmaII
AZD4818CCR1 antagonistCOPDI
CAT-354anti-IL-13 antibodyasthmaI
AZD5904

MPO inhibitor

COPDI
AZD1744Dual CCR3/H1 receptor antagonistCOPDI
AZD1236Matrix metalloproteinase inhibitionCOPDI
AZD9668Neutrophil Elastase InhibitorCOPDI
MEDI-563anti-IL-5R antibodyasthmaI
MEDI-545
anti-IFNa-antibodySLE, MyositisI
Pneumococcal
vaccine *
(MedImmune)		streptococcus
pneumoniae		I
AZD3199 iLABAasthma/COPD I  
CAM-3001anti-GM-CSFR antibodyrheumatoid arthritis I 

* Partnered product


Back to top

Discontinued Projects vs 26 July 2007 HY

NCE/Line extension
Compound
Area under investigation
Cardiovascular & Gastrointestinal
NCEAZD1283thrombosis
NCEAZD3988diabetes/obesity
NCEAZD3118arrhythmias
LECrestor Outcomes CHFCHF
LENexium NSAID GI USulcer healing
LENexium NSAID GI side effects US symptom resolution 
NCEAZD9056 Inflammatory bowel disease 
Neuroscience
NCEAZD3783anxiety & depression
NCEAZD1080 Alzheimers 
Oncology & Infection
NCEAZD6495range of tumours
NCECAT-5001solid tumours
NCEAZD5180solid tumours
NCEhMPV MAbrespiratory infection
NCEMEDI-552leukemia/lymphoma
NCEMEDI-555solid tumours
NCEMEDI-562solid tumours
NCECAT-3888hairy cell leukaemia
NCEAZD9935 solid tumours 
NCEAZD4992breast cancer 
Respiratory and Inflammation
NCEMEDI-552inflammation
NCEAnti-IL6 MAbinflammation
NCEanti Chitinase Mabasthma/COPD
NCEAZD6357 osteoarthritis 
NCE AZD6605 osteoarthritis 

 

Back to top

Comments

As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.

Compounds in development are displayed by phase.

Abbreviations:

MAA - Marketing Authorisation Application (Europe)
NDA – New Drug Application/Biologics Licensing Application (USA)
AstraZeneca websites
Search
Quick links
Information for
 Terms of use  Privacy policy    © AstraZeneca PLC 2003 - 2008